Basit öğe kaydını göster

dc.contributor.authorBalcı Isık, Yasemin
dc.contributor.authorTavil, Betül
dc.contributor.authorKarabulut, E
dc.contributor.authorKuskonmaz, Baris
dc.contributor.authorKucukbayrak, Ozlem
dc.contributor.authorAkyol, F
dc.contributor.authorHascelik, Gulsen
dc.contributor.authorCetin, Mualla
dc.contributor.authorUckan, Duygu
dc.date.accessioned2020-10-21T12:40:26Z
dc.date.available2020-10-21T12:40:26Z
dc.date.issued2011
dc.identifier.issn2146-8427
dc.identifier.urihttp://hdl.handle.net/11655/23014
dc.identifier.urihttps://doi.org/10.6002/ect.2011.0191
dc.description.abstractIn this retrospective study, cyclosporine levels at the second hour (C2 levels) were measured during oral cyclosporine intake in 28 pediatric hematopoietic stem cell transplant patients, and the relations between cyclosporine dosage and C0, C2 levels, C2/C0 ratio, and cyclosporine-related adverse effects were investigated. Cyclosporine levels at the second hour levels were found to be significantly lower in children younger than 7 years old, suggesting age-related differences in absorption and metabolism of the drug. There were statistically significant correlations of both C0 and C2 levels with blood creatinine values. In addition, a statistically significant negative relation was found between C0 and C2 levels and serum potassium levels; this unexpected finding was attributed to multiple drug effects in the early posttransplant period. The common adverse effects of cyclosporine (gingival overgrowth, gynecomastia, and hypertrichosis) were also evaluated in this study, and no correlation was found between those adverse effects and C0, C2 levels, C2/C0 ratio, and cyclosporine dosage. In the present study, despite the highly significant correlation of C2 levels with renal and metabolic effects, in pediatric hematopoietic stem cell transplant patients, measurement of C2 levels as a standard practice did not provide an advantage over C0 monitoring. However, the preliminary results suggest that C2 level monitoring could be useful in selected patients with increased risk of renal toxicity or in states where a better estimation of gastrointestinal absorption is needed
dc.language.isoentr_TR
dc.relation.isversionof10.6002/ect.2011.0191
dc.rightsinfo:eu-repo/semantics/openAccesstr_TR
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectCyclosporine leveltr_TR
dc.subjectTransplantation
dc.titleCyclosporine Level at the Second Hour in Pediatric Hematopoietic Stem Cell Transplant Patientstr_TR
dc.typeinfo:eu-repo/semantics/articletr_TR
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalEXPERIMENTAL AND CLINICAL TRANSPLANTATION
dc.contributor.departmentÇocuk Sağlığı ve Hastalıklarıtr_TR
dc.description.indexWoStr_TR
dc.fundingYoktr_TR


Bu öğenin dosyaları:

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster

info:eu-repo/semantics/openAccess
Aksi belirtilmediği sürece bu öğenin lisansı: info:eu-repo/semantics/openAccess